New study to uncover hidden heart risks of hormone therapy in transgender individuals
NCT ID NCT07394400
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This observational study will follow 94 transgender individuals for 12 months to see how gender-affirming hormone therapy affects their mood, stress, and heart health. Researchers will measure inflammation, blood vessel function, and other markers to understand potential cardiovascular risks. The goal is to improve healthcare for transgender people by providing clearer information on the benefits and risks of hormone therapy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- gender-affirming hormone therapy
- What this could lead to
- If successful, this study could help doctors better understand the risks and benefits of hormone therapy for transgender individuals, leading to safer and more personalized care.
- What could go wrong
- This is an observational study, not a treatment trial. It will not prove cause and effect, and results may take years to influence medical guidelines.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRANSGENDER INDIVIDUALS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hospital Universitario Doctor Peset
Valencia, Valencia, 46017, Spain
More trials for these conditions
Other studies related to the condition(s) this trial covers.